The adjustments include expenses related to the amortization of acquisition-related intangible assets. Revenues in Detail The company recorded an organic net sales decline of 5.9% in the reported quarter. Segmental Details Net sales in the Proprietary Products segment were $559.7 million, indicating a decline of 9.4% year over year and 8.4% on an organic basis. HVP net sales, which accounted for more than 70% of the segment's net sales, were driven by customer demand for self-injection, Envision® components ...

What's Next for West Pharmaceutical? One other stock from the same industry, Dentsply International (XRAY) , is yet to report results for the quarter ended June 2024. The results are expected to be released on July 31. West Pharmaceutical, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $702.1 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 4.83%. This compares to year-ago revenues of $753.8 million. The company has topped consensus revenue ...

West Announces Second-Quarter 2024 Results - Conference Call Scheduled for 9 a.m. EDT Today - Second-Quarter 2024 Summary (comparisons to prior-year period) • Net sales of $702.1 million declined 6.9%; organic net sales declined 5.9%. • Reported-diluted EPS of $1.51, compared to $2.06 in the same period last year. • Adjusted-diluted EPS of $1.52, compared to $2.11 in the same period last year. • The Company is updating full-year 2024 net sales guidance to a range of $2.870 billion to $2.900 billion, compare ...

EXTON, Pa., July 25, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2024 and updated full-year 2024 financial guidance. To participate in the conference call by asking questions to Management, please register in advance by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that will be used to access the call. | --- | --- | --- | --- | --- | --- | --- | - ...

Q2 Estimates Factors to Note However, destocking, as well as the timing of new high-value product (HVP) device capacity and customer-led HVP upgrade, is likely to have led to a decline in second-quarter sales. Moreover, a weak pharma market and declining sales related to COVID-19 vaccines are expected to have offset growth in other products. The company is also expected to have witnessed a gross margin expansion in the aforementioned segment. This was likely due to a favorable mix of products sold (stemming ...

EXTON, Pa., July 11, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter financial results before the market opens on Thursday, July 25, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. Management will refer to a slide presentation during the call, which will be made available on the day of the ...

First-Quarter 2024 | --- | --- | |-----------------------------------|--------------------------------------------| | $695.4M | First Quarter Overall Net Sales \| 3.0% | | | | | Diluted Earnings Per Share: $1.55 | Adjusted Diluted Earnings Per Share: $1.56 | WST Q1 2024 Earnings 1 "We had a solid start to the year and our full-year 2024 financial outlook remains unchanged. We are actively managing the timing of inventory decisions by some of our customers, and our recent order trends reinforce our prior out ...

West Pharmaceutical Services, Inc. (NYSE:WST) Q1 2024 Earnings Conference Call April 25, 2024 9:00 AM ET Company Participants Quintin Lai - Vice President, Strategy and Investor Relations Eric Green - President and Chief Executive Officer Bernard Birkett - Senior Vice President, Chief Financial and Operations Officer Conference Call Participants Matt Larew - William Blair Jacob Johnson - Stephens Paul Knight - KeyBanc Michael Ryskin - Bank of America Justin Bowers - Deutsche Bank David Windley - Jefferies ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 23-1210010 (State or o ...

Exhibit 99.1 West Announces First-Quarter 2024 Results and Declares Third-Quarter 2024 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, April 25, 2024 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2024 and updated full-year 2024 financial guidance. First-Quarter 2024 Summary (comparisons to prior-year period) "Adjusted-diluted EPS" and "organic sales growth" are Non-U.S. GAAP measurements. See discussion under the heading " ...